- Home
- ELA vs ELDN Comparison
ELA vs ELDN Comparison
Compare ELA & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELA
- ELDN
- Stock Information
- Founded
- ELA 1965
- ELDN 2004
- Country
- ELA United States
- ELDN United States
- Employees
- ELA N/A
- ELDN N/A
- Industry
- ELA Consumer Specialties
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- ELA Consumer Discretionary
- ELDN Health Care
- Exchange
- ELA Nasdaq
- ELDN Nasdaq
- Market Cap
- ELA 156.2M
- ELDN 178.4M
- IPO Year
- ELA N/A
- ELDN N/A
- Fundamental
- Price
- ELA $5.82
- ELDN $2.72
- Analyst Decision
- ELA Strong Buy
- ELDN Strong Buy
- Analyst Count
- ELA 1
- ELDN 2
- Target Price
- ELA $9.00
- ELDN $12.50
- AVG Volume (30 Days)
- ELA 30.7K
- ELDN 198.6K
- Earning Date
- ELA 08-06-2025
- ELDN 08-18-2025
- Dividend Yield
- ELA N/A
- ELDN N/A
- EPS Growth
- ELA 15.15
- ELDN N/A
- EPS
- ELA 0.28
- ELDN N/A
- Revenue
- ELA $188,774,278.00
- ELDN N/A
- Revenue This Year
- ELA $7.61
- ELDN N/A
- Revenue Next Year
- ELA $6.27
- ELDN N/A
- P/E Ratio
- ELA $21.13
- ELDN N/A
- Revenue Growth
- ELA 14.19
- ELDN N/A
- 52 Week Low
- ELA $4.20
- ELDN $2.30
- 52 Week High
- ELA $7.88
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- ELA 46.11
- ELDN 35.43
- Support Level
- ELA $5.61
- ELDN $2.76
- Resistance Level
- ELA $6.12
- ELDN $2.90
- Average True Range (ATR)
- ELA 0.28
- ELDN 0.16
- MACD
- ELA 0.02
- ELDN -0.03
- Stochastic Oscillator
- ELA 55.68
- ELDN 4.39
About ELA Envela Corporation
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.